Orillion A., A. Hashimoto, et al. (2017). “Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma.” Clin Cancer Res. DOI: 10.1158/1078-0432.CCR-17-0741
Johnson M. et al. (2017, June). “ENCORE 601: A Phase 2 study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.” Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL.
Johnson M., A. Adjei, et al. (2016, November). “Dose-escalation/confirmation results of ENCORE 601, a Phase 1b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non–small cell lung cancer (NSCLC).” Poster presented at the Society for the Immunotherapy of Cancer Annual Meeting, National Harbor, MD.
Gameiro SR, AS Malamas, et al. (2016). “Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.” Oncotarget. 7(7):7390-402.
Zhu S., C. Denman, et al. (2013). “The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.” Pharm. Res. 32(3): 779–92.
Shen, L., M. Ciesielksi, et al. (2012). “Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.” PLoSOne. 7(1): e30815.